MX2013004899A - Composicion de anticuerpos pan-her. - Google Patents

Composicion de anticuerpos pan-her.

Info

Publication number
MX2013004899A
MX2013004899A MX2013004899A MX2013004899A MX2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A
Authority
MX
Mexico
Prior art keywords
family
pan
antibody compositions
antibody composition
directed
Prior art date
Application number
MX2013004899A
Other languages
English (en)
Other versions
MX347981B (es
Inventor
Johan Lantto
Mikkel Wandahl Pedersen
Michael Kragh
Helle Jacobsen
Ida K Christensen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004899A publication Critical patent/MX2013004899A/es
Publication of MX347981B publication Critical patent/MX347981B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a las terapéuticas mejoradas contra los receptores dentro de la familia EGFR/ErbB/HER que interfieren más ampliamente con múltiples miembros de la familia HER (inhibición pan-HER). Más particularmente, la invención está dirigida al uso de las composiciones de anticuerpo para la terapia contra el cáncer humano. Los estudios in vitro han mostrado que las composiciones de anticuerpo de la invención que se dirigen a múltiples receptores de la familia HER, son superiores a las composiciones de anticuerpo que se dirigen únicamente a un receptor de la familia HER.
MX2013004899A 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her. MX347981B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (2)

Publication Number Publication Date
MX2013004899A true MX2013004899A (es) 2013-07-15
MX347981B MX347981B (es) 2017-05-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Country Status (13)

Country Link
US (1) US9217039B2 (es)
EP (3) EP3156421B1 (es)
JP (2) JP6186277B2 (es)
KR (2) KR101773120B1 (es)
AU (2) AU2011324871B2 (es)
CA (2) CA2816520C (es)
DK (1) DK2635604T3 (es)
ES (2) ES2616961T3 (es)
IL (2) IL225953A0 (es)
MX (2) MX348637B (es)
PL (1) PL2635604T3 (es)
TW (1) TW201231066A (es)
WO (2) WO2012059858A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009287163B2 (en) * 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
JP6186277B2 (ja) 2010-11-01 2017-08-23 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ３抗体および組成物
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
WO2012156975A1 (en) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
PL2726600T3 (pl) * 2011-07-01 2017-08-31 Amgen Inc. Hodowla ssaczych komórek
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AU2013255537B2 (en) 2012-05-02 2018-02-15 Symphogen A/S Humanized pan-her antibody compositions
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
HUE044730T2 (hu) 2013-09-20 2019-11-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
EP3847194A1 (en) * 2018-09-07 2021-07-14 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
MA54944A (fr) * 2019-02-14 2021-12-22 Merus Nv Combinaisons de fractions de liaison se liant à egfr, her2 et her3
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CN1214044C (zh) * 1996-03-27 2005-08-10 基因技术股份有限公司 ErbB3抗体
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
PL1787126T3 (pl) 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
JP2008507520A (ja) 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド Ｈｅｒ２抗体組成物
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
SI2129396T1 (sl) * 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
WO2008104183A2 (en) 2007-03-01 2008-09-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
SI2152872T1 (sl) 2007-05-25 2011-01-31 Symphogen As Postopek za pripravo rekombinantnega poliklonskega proteina
MX2010005377A (es) 2007-11-22 2010-06-25 Symphogen As Metodo para caracterizacion de proteina policlonal recombinante.
CN102007146A (zh) 2008-04-23 2011-04-06 西福根有限公司 用于制备多克隆蛋白质的方法
EA022884B1 (ru) 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА
AU2009287163B2 (en) * 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
BRPI0920032A2 (pt) 2008-10-06 2017-06-27 Symphogen As método para identificar e selecionar candidatos a fármacos para produtos farmacológicos combinatórios
SG174378A1 (en) * 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
SG175077A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
CN102378768A (zh) * 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
EP2425009A4 (en) 2009-04-29 2013-01-23 Trellis Bioscience Llc IMMUNOREACTIVE ENHANCED ANTIBODIES WITH HEREGULINE COUPLE HER3
US9050375B2 (en) * 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
WO2011022727A2 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
RS56741B1 (sr) 2009-11-13 2018-03-30 Daiichi Sankyo Europe Gmbh Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3
JP6039428B2 (ja) 2010-03-04 2016-12-07 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ２抗体および組成物
SG184452A1 (en) * 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
CN103080134B (zh) * 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
JP6186277B2 (ja) 2010-11-01 2017-08-23 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ３抗体および組成物

Also Published As

Publication number Publication date
KR101862832B1 (ko) 2018-05-30
AU2011324870B2 (en) 2015-01-29
EP2635605B1 (en) 2018-07-25
US20130287684A1 (en) 2013-10-31
WO2012059858A1 (en) 2012-05-10
AU2011324870A1 (en) 2013-01-31
DK2635604T3 (en) 2017-02-27
AU2011324871A1 (en) 2013-05-09
US9217039B2 (en) 2015-12-22
CA2816519C (en) 2019-01-15
EP2635605A1 (en) 2013-09-11
WO2012059857A3 (en) 2012-07-19
TW201231066A (en) 2012-08-01
IL225954A0 (en) 2013-07-31
PL2635604T3 (pl) 2017-09-29
MX2013004897A (es) 2013-07-15
CA2816520C (en) 2017-11-21
IL225954B (en) 2018-05-31
EP3156421B1 (en) 2018-06-06
JP2014503188A (ja) 2014-02-13
CA2816519A1 (en) 2012-05-10
AU2011324871B2 (en) 2016-05-19
JP6186277B2 (ja) 2017-08-23
CA2816520A1 (en) 2012-05-10
JP6033783B2 (ja) 2016-11-30
KR101773120B1 (ko) 2017-08-30
EP3156421A1 (en) 2017-04-19
KR20140026336A (ko) 2014-03-05
MX348637B (es) 2017-06-22
ES2692379T3 (es) 2018-12-03
KR20140026337A (ko) 2014-03-05
IL225953A0 (en) 2013-07-31
EP2635604B1 (en) 2016-11-30
ES2616961T3 (es) 2017-06-14
EP2635604A2 (en) 2013-09-11
MX347981B (es) 2017-05-22
EP2635605A4 (en) 2014-10-22
WO2012059857A2 (en) 2012-05-10
JP2014503189A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
MX347981B (es) Composicion de anticuerpos pan-her.
NZ604003A (en) Monoclonal antibodies against her2
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
NZ626610A (en) Antibodies that bind csf1r
IN2012DN02081A (es)
TN2012000462A1 (en) Anti-cd40 antibodies
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
CU20140036A7 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
EA020330B3 (ru) Хиназолиновые соединения
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
NZ602992A (en) Prophylaxis of colorectal and gastrointestinal cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
JO3096B1 (ar) الأجسام المضادة لمستقبل ii مضاد tgfb
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello

Legal Events

Date Code Title Description
FG Grant or registration